重组人血管内皮抑制素联合腔内化疗治疗恶性胸腹水的临床观察

目的　观察重组人血管内皮抑制素（恩度）联合腔内化疗治疗恶性胸腹水患者的疗效和安全性。方法　８０例恶性胸腹水患者分为腔内恩度联合化疗组（治疗组）和腔内化疗组（对照组）。治疗前均先排尽胸腹水，治疗组在胸腔内注入顺铂（ＤＤＰ）６０ｍｇ和恩度６０ｍｇ，在腹腔内注入ＤＤＰ６０ｍｇ、氟尿嘧啶（５-ＦＵ）１.０ｇ和恩度６０ｍｇ。对照组除不加入恩度外，其余同治疗组。结果　在可评价的７６例患者中，治疗组总有效率为７９.１％，对照组５７.６％，其中治疗组恶性胸水患者的有效率为８８９％，恶性腹水患者为７２.０％；对照组恶性胸水患者的有效率为６０.０％，恶性腹水患者为５５.６％，两组疗效差异显著（Ｐ＜０.０５）。全组患者耐受良好，无严重不良反应。治疗组中位生存期为５.８个月，略长于对照组的４.６个月，但两组差异无统计学意义（Ｐ＞０.０５）。结论　腔内恩度联合化疗治疗恶性胸腹水有效且安全。

Clinical observation of the efficacy of intracavitary injection of endostar combined with chemotherapy on malignant pleural effusion and ascites

Objective To study the efficacy and safety of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion and ascites.Methods Eighty cases of the patients with malignant pleural effusion and ascites were divided into groups of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion and ascites(treatment group)and groups of intracavitary chemotherapy(control group).Pleural effusion and ascites of the patients from the two groups were both ...